These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1032 related articles for article (PubMed ID: 27607580)

  • 21. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.
    Kumar K; Raza SS; Knab LM; Chow CR; Kwok B; Bentrem DJ; Popovic R; Ebine K; Licht JD; Munshi HG
    Sci Rep; 2015 Mar; 5():9489. PubMed ID: 25807524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
    Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
    Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
    Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
    Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.
    Riveiro ME; Astorgues-Xerri L; Vazquez R; Frapolli R; Kwee I; Rinaldi A; Odore E; Rezai K; Bekradda M; Inghirami G; D'Incalci M; Noel K; Cvitkovic E; Raymond E; Bertoni F
    Oncotarget; 2016 Dec; 7(51):84675-84687. PubMed ID: 27835869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
    Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
    Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs.
    Huang Y; Yang X; Xu T; Kong Q; Zhang Y; Shen Y; Wei Y; Wang G; Chang KJ
    Int J Oncol; 2016 Jul; 49(1):153-63. PubMed ID: 27210546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
    Bouillez A; Rajabi H; Pitroda S; Jin C; Alam M; Kharbanda A; Tagde A; Wong KK; Kufe D
    Cancer Res; 2016 Mar; 76(6):1538-48. PubMed ID: 26833129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
    Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
    Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-treatment of birinapant with TRAIL synergistically induces apoptosis by downregulating cFLIP(L) in MDA-MB-453 cell lines.
    Park EJ; Kim HD; Choi EK; Hoe KL; Kim DU
    Biochem Biophys Res Commun; 2020 Dec; 533(3):289-295. PubMed ID: 32958259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.
    Bao YX; Zhao XD; Deng HB; Lu CL; Guo Y; Lu X; Deng LL
    Cell Oncol (Dordr); 2016 Aug; 39(4):343-52. PubMed ID: 27016208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells.
    Lippa MS; Strockbine LD; Le TT; Branstetter DG; Strathdee CA; Holland PM
    Apoptosis; 2007 Aug; 12(8):1465-78. PubMed ID: 17440816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.
    Guo J; Liu Y; Lv J; Zou B; Chen Z; Li K; Feng J; Cai Z; Wei L; Liu M; Pang X
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
    Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
    Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in
    Adeegbe DO; Liu S; Hattersley MM; Bowden M; Zhou CW; Li S; Vlahos R; Grondine M; Dolgalev I; Ivanova EV; Quinn MM; Gao P; Hammerman PS; Bradner JE; Diehl JA; Rustgi AK; Bass AJ; Tsirigos A; Freeman GJ; Chen H; Wong KK
    Cancer Immunol Res; 2018 Oct; 6(10):1234-1245. PubMed ID: 30087114
    [No Abstract]   [Full Text] [Related]  

  • 36. Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions.
    Zhuang H; Jiang W; Zhang X; Qiu F; Gan Z; Cheng W; Zhang J; Guan S; Tang B; Huang Q; Wu X; Huang X; Jiang W; Hu Q; Lu M; Hua ZC
    J Mol Med (Berl); 2013 Feb; 91(2):219-35. PubMed ID: 22948392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
    Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
    Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
    Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
    Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer.
    Li QQ; Xie YK; Wu Y; Li LL; Liu Y; Miao XB; Liu QZ; Yao KT; Xiao GH
    Oncotarget; 2017 Feb; 8(7):12067-12080. PubMed ID: 28076844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
    Zhu K; Fang W; Chen Y; Lin S; Chen X
    Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.